Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1701
Peloton Interactive
PTON
$2.44B
| $9.68M | ﹤0.01% |
1,570,742
+78,191
| +5% | +$550K |
|
1702
AptarGroup
ATR
$8.43B
| $9.66M | ﹤0.01% |
79,227
-13,364
| -14% | -$1.65M |
|
1703
Lantheus
LNTH
$6.59B
| $9.66M | ﹤0.01% |
145,098
-17,633
| -11% | -$1.03M |
|
1704
TeraWulf
WULF
$8.14B
| $9.64M | ﹤0.01% |
839,323
+176,356
| +27% | +$2.36M |
|
1705
Arcutis Biotherapeutics
ARQT
$3.25B
| $9.63M | ﹤0.01% |
331,578
+5,610
| +2% | +$144K |
|
1706
Capital Group Growth ETF
CGGR
$25.3B
| $9.59M | ﹤0.01% |
215,654
+133,231
| +162% | +$5.88M |
|
1707
CALL
Ivanhoe Electric
IE
$1.66B
| $9.59M | ﹤0.01% |
600,000
+100,000
| +20% | +$1.43M |
|
1708
Oscar Health
OSCR
$9.5B
| $9.58M | ﹤0.01% |
666,744
+269,304
| +68% | +$4.66M |
|
1709
Dana Inc
DAN
$3.26B
| $9.55M | ﹤0.01% |
401,829
+162,276
| +68% | +$3.43M |
|
1710
Ryman Hospitality Properties
RHP
$7.87B
| $9.54M | ﹤0.01% |
100,809
+8,145
| +9% | +$752K |
|
1711
Polaris
PII
$3.91B
| $9.54M | ﹤0.01% |
150,757
+10,639
| +8% | +$701K |
|
1712
CALL
Lockheed Martin
LMT
$138B
| $9.53M | ﹤0.01% |
19,700
-100
| -0.5% | -$47.9K |
|
1713
RBC Bearings
RBC
$17.5B
| $9.53M | ﹤0.01% |
21,244
-8,580
| -29% | -$3.63M |
|
1714
EastGroup Properties
EGP
$11B
| $9.52M | ﹤0.01% |
53,462
-9,984
| -16% | -$1.77M |
|
1715
Clean Harbors
CLH
$16.9B
| $9.52M | ﹤0.01% |
40,594
-13,297
| -25% | -$3.04M |
|
1716
Viper Energy
VNOM
$14.8B
| $9.51M | ﹤0.01% |
246,153
+96,826
| +65% | +$3.67M |
|
1717
PUT
Capricor Therapeutics
CAPR
$244M
| $9.49M | ﹤0.01% |
328,900
+244,800
| +291% | +$3.2M |
|
1718
SSR Mining
SSRM
$6.49B
| $9.49M | ﹤0.01% |
432,758
+37,024
| +9% | +$824K |
|
1719
Lincoln Electric
LECO
$15.5B
| $9.48M | ﹤0.01% |
39,574
-30,717
| -44% | -$7.28M |
|
1720
Boot Barn
BOOT
$4.92B
| $9.47M | ﹤0.01% |
53,669
+4,625
| +9% | +$863K |
|
1721
ADT
ADT
$5.46B
| $9.4M | ﹤0.01% |
1,164,391
+779,312
| +202% | +$6.48M |
|
1722
CALL
Core Scientific
CORZ
$6.36B
| $9.39M | ﹤0.01% |
645,100
-1,287,300
| -67% | -$22.4M |
|
1723
Acuity Brands
AYI
$10.8B
| $9.37M | ﹤0.01% |
26,032
-1,939
| -7% | -$701K |
|
1724
Wintrust Financial
WTFC
$11B
| $9.33M | ﹤0.01% |
66,704
-99,179
| -60% | -$13.2M |
|
1725
Green Plains
GPRE
$1.09B
| $9.32M | ﹤0.01% |
950,737
+209,100
| +28% | +$2.1M |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.